- Gold Is in a 'Bubble' And Will Keep Going Higher: Gartman
- Millions May Have to Repay Part of Obama Tax Credit
- Madoff Auction: $4,750 for a Decoy Duck?
- Slideshow: Madoff's Luxury Boats Go Up for Auction
- Retail Sales Show Gain, But Manufacturing Gauge Slips
- Business Inventories Fall 0.4% in September
- Intel Plans to Increase Dividend 12.75%; Shares Gain
- Several Credit Card Companies See Default Rate Fall
- Fed Proposes Crackdown on Excessive Gift-Card Fees
- S&P to Hit 1,175 in the Short Term: Strategist
- Your Jobless Recovery Game Plan
- S&P to Hit 1,175 in the Short Term: Strategist
- Busch: US Health Care Bill a Concern for the Chinese
- Underwater Mortgages Could Sink Even Deeper
- My Market and Fed Outlook Now: BlackRock's Doll
- Farrell: The Market is Still Seeking Reassurance
- GM Cuts Losses—Plans Early Loan Repayment
- Schork Oil Outlook: Still Bearish Crude, But Skeptical
MOST SHARED
- BlackRock: Central Banks To Be Net Buyers of Gold
- Millions May Have to Repay Part of Obama Tax Credit
- Gold Is in a 'Bubble' And Will Keep Going Higher: Gartman
- Weak US Housing Market Drags on Lowe's Profit
- Cisco Ups Tandberg Bid, Claims Over 40% Backing
- Madoff Auction: $4,750 for a Decoy Duck?
- EADS Cautious on Full-Year Forecast after Earnings Dip
- Devon to Sell its Gulf, International Assets
Text Size 
Roche on Tuesday said a late-stage study of its cancer drug Avastin in combination with gemcitabine chemotherapy and Tarceva for pancreatic cancer did not meet the primary endpoint for survival.
The phase III trial comparing gemcitabine chemotherapy and Tarceva with or without Avastin as first-line treatment for advanced pancreatic cancer showed some evidence of clinical activity on secondary endpoints but the trial did not meet the primary endpoint of overall survival, Roche said in a statement.
Data from the AVITA trial are now being further analyzed to determine the extent of benefit of adding Avastin to the Tarceva/gemcitabine combination therapy, Roche said.
Avastin is made by U.S. biotech firm Genentech [DNA
Loading...
()
] , which is majority owned by Swiss drugmaker Roche Holding.
Print
Email
- Where, what, how.
- CNBC's Jim Goldman asks: Has the sun begun to set on Twitter? Data suggests its best days are over.
- De Loach Vineyards is selling its pinot noir the old fashioned way, helping to cut energy and transportation costs.
- Why are the Chinese concerned about the progress of U.S. health care legislation?
- The president and founder of Genesis Today wants to improve America’s health, and thinks Wal-Mart can help.
- If a terrible driver on your morning commute has you feeling like you want to scream, check this out.
Data is a real-time snapshot *Data is delayed at least 15 minutes